TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)-- Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd.(NYSE and TASE: TEVA), today announced the availability ofa generic version of NuvaRing®1 (etonogestrel and ethinyl estradiol vaginal ring), 0.120 mg/0.015 mg per day, in the U.S. Teva’s AB-rated and bioequivalent etonogestrel and ethinyl estradiol vaginal ring, is an estrogen/progestin combination hormonal contraceptive (CHC) indicated for use by women to prevent pregnancy.
Class II recall of Captopril Tablets, USP 12.5 mg by Wockhardt USA Inc.